FierceMarkets

FierceMarkets
Share

FierceMarkets

 •  December 1

Already scrambling to deal with a shortage of saline in the U.S., the FDA now says it also is taking extraordinary measures to help get hospitals supplies of products needed to intravenously feed infants after production was also disrupted by hurricane damage in Puerto Rico. The FDA is working with Baxter to import products it produces for IV...

FierceMarkets

 •  November 30

Wednesday, multiple myeloma med Darzalex hit a development milestone, triggering a $20 million payment from Johnson & Johnson for Genmab. But the way one analyst sees it, the Big Pharma may eventually tire of shelling out payments and take matters into its own hands. Bernstein’s Wimal Kapadia sees “takeout potential” in Genmab’s future, he wrote in...

FierceMarkets

 •  November 29

Novartis has the option to sell its stake in its GlaxoSmithKline consumer health JV to its partner. But it doesn’t sound like that’s what the Swiss drugmaker’s plotting. As outgoing CEO Joe Jimenez and successor Vas Narasimhan told Bernstein analyst Tim Anderson, the company believes there are a couple years to go before the venture reaches its...

FierceMarkets

 •  November 10

Still dealing with intense pricing pressure in its key diabetes business, Novo Nordisk has decided to cut 185 jobs in its commercial organization and add another 70, a spokesperson told FiercePharma. The company is "evolving its commercial model to position the organization to be more competitive, withstand market challenges and fully leverage the...

FierceMarkets

 •  November 9

Seqirus not only makes seasonal vaccines to help protect consumers against the flu, it also is contracted by the UK government to be in constant a state of readiness in case of a pandemic. That has prompted the world's second-largest flu vaccine maker to invest another £40 million to its site in Liverpool and add about 100 jobs so it can shorten...

FierceMarkets

 •  November 6

As the world’s largest generics maker, Teva still doesn’t have much of a presence in China, even though it is a country relies heavily on generics. The Israeli company is looking to remedy that by reportedly forming a joint venture with local company Guangzhou Pharma, according to Bloomberg. The intel came from a Bloomberg interview with Li...

FierceMarkets

 •  October 26

GlaxoSmithKline and Reckitt Benckiser have already declared their interest in Pfizer’s consumer health unit. But they likely won’t be alone when bidding kicks off. Companies including Sanofi, Johnson & Johnson and Procter & Gamble could also look to snag the unit, sources told Reuters, and Pfizer’s hoping competition can help it reap at least $20...

FierceMarkets

 •  October 24

An Akorn sterile injectables plant in Illinois is in hot water with the FDA again, but this time it may be a problem for Fresenius Kabi, which is buying the generics manufacturer in a $4.3 billion deal. According to a recently posted FDA Form 483, the agency found new issues with Akorn’s sterile manufacturing during an inspection of the Decatur...

FierceMarkets

 •  October 24

As promising Ebola vaccines from global drugmakers GlaxoSmithKline and Merck & Co. still await official licenses, China has approved its own shot, co-developed by the Chinese Academy of Military Medical Sciences’ Bioengineering Institute and domestic vaccine specialist Tianjin CanSino Biologics. Dubbed Ad5-EBOV, the recombinant adenovirus...

FierceMarkets

 •  October 23

Despite being one of the most expensive drugs in the world, GlaxoSmithKline's gene therapy Strimvelis won the backing of the often stingy U.K. cost watchdogs to treat a rare disease called ADA-SCID, or "bubble boy" syndrome. The drug, which costs €594,000 (about $700,000), is a one-time treatment that the overseers said is worth the...